Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024)

Vir Biotechnology has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $11.0 million for Q4 2024.

• Asset Writedowns and Impairment for Q4 2024 came in at $11.0 million, up 300.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.0 million (down 20.0% YoY), and the FY2024 annual result was $14.6 million, up 50.65% from the prior year.
• Asset Writedowns and Impairment came in at $11.0 million for Q4 2024 at Vir Biotechnology, up from $2.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $11.0 million in Q4 2024 to a low of $800000.0 in Q3 2020.
• The 3-year median for Asset Writedowns and Impairment is $2.8 million (2023), against an average of $4.9 million.
• Peak annual rise in Asset Writedowns and Impairment reached 300.07% in 2024, while the deepest fall reached 300.07% in 2024.
• Vir Biotechnology's Asset Writedowns and Impairment stood at $800000.0 in 2020, then jumped by 244.88% to $2.8 million in 2023, then surged by 300.07% to $11.0 million in 2024.
• The last three Asset Writedowns and Impairment figures came in at $11.0 million (Q4 2024), $2.8 million (Q4 2023), and $800000.0 (Q3 2020), per Business Quant data.